The transition from the lab to the clinic is one of the most exciting times small biopharmaceutical companies experience in their lifecycle. It can also be one of the most stressful and perilous. While there are a variety of potential pitfalls to be navigated, there is one area which is most disruptive: On-time patient enrollment and strong patient retention. Today, this topic is often holistically described as “Patient Engagement”.
As most small development firms are funded through milestone driven investments by private equity, managing clinical trial timelines and efficiency become paramount in achieving success. Statistically, there is no bigger challenge these firms face than on-time enrollment of studies. It is the number 1 or 2 cause of study delay in every analysis performed over the past 15 years. With daily operating costs for a pivotal trial running $60K and up for most companies, the stakes are high.
This presentation will focus on helping young drug development companies address this challenge and be better positioned for a successful early run in the clinic. Specifically, we will share proven, TA-focused approaches, which companies can take to develop enrollment plans and execute recruitment and retention initiatives to shorten timelines and achieve key investment milestones.
Melynda Geurts| Vice President of Operations, Imperial Clinical Research Services